Menu
Recruiting NCT07738991

A Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of NKF-PEG, and US-Neulasta in Healthy Adult Male Volunteers

Phase I Interventional Healthy Participants

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: NKF-PEG, US-Neulasta.
Who it may be relevant to
Registry conditions: Healthy Participants. Basic parameters: 18 years — 55 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Single Center, Single-Dose, Double-Blind, Randomized, Two-Period, Crossover Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-PEG, and US-Neulasta®, and to Evaluate Safety in Healthy Adult Male Volunteers

Overview

A Single Center, Single-Dose, Double-Blind, Randomized, Two-Period, Crossover Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-PEG, and US-Neulasta®, and to Evaluate Safety in Healthy Adult Male Volunteers

Detailed description

Participants will be admitted to the clinical research unit (CRU) on Day -1. Eligible participants will be randomized (1:1) on Day -1 to 1 of 2 treatment sequences. Participants will then receive a single 6 mg SC dose during Treatment Period 1 of either NKF-PEG, or US-Neulasta, according to the randomization schedule. Participants will be discharged from the CRU on Day 13 and will return to the CRU on Day 16 for PK/PD analysis and for safety assessments.

Following the washout period of 6 weeks, the same schedule will be followed for Treatment Period 2, where participants will receive a single 6 mg SC dose of the final product according to their treatment sequence, then discharge from the CRU on Day 13 of Treatment Period 2 and will return for ambulatory visits on Day 16 of Treatment Period 2 and Safety Visit (Day 84).

Interventions

  • Biological NKF-PEG
    NKF-PEG administered as a single 6 mg SC dose in the periumbilical area
  • Biological US-Neulasta
    US-Neulasta administered as a single 6 mg SC dose in the periumbilical area

Primary outcome measures

  • AUC0-t [Time frame: 0 to 360 hours]
  • Cmax [Time frame: 0 to 360 hours]
  • AUEC0- t for ANC [Time frame: 0 to 360 hours]
  • Emax of ANC [Time frame: 0 to 360 hours]
Secondary outcome measures (12)
  • AUC0-inf [Time frame: 0 to 360 hours]
  • Tmax [Time frame: 0 to 360 hours]
  • T1/2 [Time frame: 0 to 360 hours]
  • Tmax of ANC [Time frame: 0 to 360 hours]
  • Tmax of CD34+ cell count [Time frame: 0 to 360 hours]
  • AUEC0-t of CD34+ cell count [Time frame: 0 to 360 hours]
  • Emax of CD34+ cell count [Time frame: 0 to 360 hours]
  • The proportion of participants with treatment-induced anti-pegfilgrastim antibodies at any time during the study [Time frame: 0-84 days]
  • The proportion of participants with treatment-induced anti-filgrastim antibodies at any time during the study [Time frame: 0-84 days]
  • The proportion of participants with treatment-induced anti-PEG antibodies at any time during the study [Time frame: 0-84 days]
  • The proportion of participants with post dose positive neutralizing antibody result of pegfilgrastim at any time during the study [Time frame: 0-84 days]
  • Adverse event (AE) assessments (including injection site reactions) [Time frame: 0-84 days]

Eligibility criteria

Inclusion criteria

  • Participant must be 18 to 55 years of age, at the time of signing the informed consent.
  • Body weight ≥ 50 kg and body mass index (BMI) within the range 18.5-30.0 kg/m2 (inclusive).
  • Male assigned at birth, inclusive of all gender identities. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

a. Male participants:

Participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of study intervention:

•Refrain from donating sperm

PLUS, either:

Be abstinent from intercourse where pregnancy can occur (abstinent on a long term and persistent basis) and agree to remain abstinent.

OR

Must agree to use contraception as detailed below:

Agree to use birth control (2 highly effective methods of contraception including 1 barrier method) when having sexual intercourse with a partner able to give birth who is not currently pregnant.

  • Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Willingness to follow protocol defined restrictions and Investigator/staff instructions and protocol procedures.

Exclusion criteria

  • Sensitivity to any of the study interventions, or components thereof including E. coli derived proteins, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
  • With any clinically significant abnormalities identified during screening in physical examination, vital signs, laboratory tests, or 12-lead ECG.
  • History or presence of cardiovascular, respiratory, psychiatric, metabolic, hepatic, renal, gastrointestinal, endocrinological, hematological, oncological, or neurological disorders determined to be clinically significant by the Investigator.
  • Evidence of active infection, including chronic or localized infections, by history, physical examination findings, or laboratory data, as determined by the Investigator within 1 week prior to Day 1.
  • Rash, scarring, dermatological condition, or tattoo in the area of the injection site that could interfere with the injection or injection site assessment.
  • History or presence of any condition that in the opinion of the Investigator would constitute a risk when taking the study intervention or interfere with the interpretation of data.
  • A history of alcohol abuse within 3 months prior to screening (alcohol consumption of more than 14 units per week: 1 unit of alcohol = 285 mL beer, or 25 mL spirits, or 100 mL wine).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Other

Study locations

China · 1 center
  • Ethics Committee of Hopeshine-Minsheng Hospital of Xinzheng, Zhengzhou, — Zhengzhou

Identifiers

NCT: NCT07738991 · NKF-PEG-101

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗